Physician profile
Timothy Tsoi
NPI 1982765327
$32,298.62
in general payments reported to CMS, 2019-2025
15 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $245 · 2021: $1,738 · 2022: $7,556 · 2023: $14K · 2024: $7,348 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,052 · Travel and Lodging: $2,825 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,625.00 |
| Food and Beverage | $3,052.04 |
| Travel and Lodging | $2,824.83 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28,242.37 | 2020-2024 | Watchman Access System, Watchman Flx |
| Atricure, INC. | $2,341.70 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Astrazeneca Pharmaceuticals LP | $342.93 | 2021-2023 | Brilinta |
| Janssen Pharmaceuticals, INC | $182.09 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $148.35 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.22 | 2023-2024 | Lifevest |
| Edwards Lifesciences Corporation | $132.58 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $125.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $107.78 | 2021 | |
| Novo Nordisk INC | $98.39 | 2025 | Ozempic |
| Pfizer INC. | $92.98 | 2019 | |
| Cvrx, INC. | $89.04 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.81 | 2022 | |
| Electromed, INC. | $83.33 | 2024 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $79.52 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tsoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.